Netherlands Pharmaceuticals and Healthcare Report Q3 2014

  • May 2014
  • -
  • Business Monitor International
  • -
  • 115 pages

Includes 3 FREE quarterly updates
BMI View:

Despite Netherlands' expectations for a return to positive economic growth in 2014, its
government will continue with austerity measures to comply with EU budget criteria. Drugmakers have
generally charged what the market will bear in both developed and emerging markets. With the advent of
health economics, coupled with increasing budget deficits, there will be more caps on medicine expenditure
in the near future, particularly on essential drugs. We therefore maintain that further restrictions on
medicines prices will work to create a subdued outlook for patented and generic drugmakers operating in
the country.

Headline Expenditure Projections

- Pharmaceuticals: EUR6.09bn (USD8.04bn) in 2013 to EUR5.94bn (USD7.78bn) in 2014; -2.4% in
local currency terms and -3.1% in US dollar terms.
- Healthcare: EUR74.69bn (USD98.59bn) in 2013 to EUR76.21bn (USD99.83bn) in 2014; 2.0% in local
currency terms and -1.3% in US dollar terms.

Risk/Reward Ratings

The Netherlands continues to rank in the lower half of BMI's Pharmaceutical
Risk/Reward Ratings
(RRRs)
for the 15 key Western European markets, falling one place to 11th in our ratings for Q314. The country fell
from eighth in Q413. At an unchanged 66, its overall RRR score remains only slightly below the regional
average of 67. This was the result of the rise of Finland and the incorporation of Denmark in our ratings
system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk
operating environment, poor market prospects - due to pressures on pricing and reimbursement and the
market's maturity - will continue to weigh down the country's overall standing.

Table Of Contents

Netherlands Pharmaceuticals and Healthcare Report Q3 2014
BMI Industry View ...... 7
SWOT ...... 9
Political ................... 11
Economic ................. 12
Business Environment 13
Industry Forecast ..... 14
Pharmaceutical Market Forecast ....... 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2010-2018) . 16
Healthcare Market Forecast ............. 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018) . . . . . . 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018) . . . . . . . 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018) . . . . . . . . . . . . 19
Prescription Drug Market Forecast ... 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018) 22
Patented Drug Market Forecast ........ 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018) . . . . 24
Netherlands .............. 24
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018) . . . . 26
OTC Medicine Market Forecast ........ 26
Table: OTC Medicine Sales Indicators By Category, 2008-2010 . . . . . . . . . . . 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018) . . . . . . . . . . . . 29
Pharmaceutical Trade Forecast ........ 30
Table: Pharmaceutical Trade Data And Forecast (Netherlands 2012-2018) . . . . . . . . . . . . . . 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2012-2018) . . . . . . . . . . . . 31
Other Healthcare Data .................... 32
Table: Number Of Physicians By Type, 2007-2010 . . . . . . . . . . 33
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts ........... 35
Economic Analysis ..... 35
Table: Netherlands - Economic Activity . . . . . . . 38
Industry Risk Reward Ratings ...... 39
Western Europe Risk/Reward Ratings . 39
Netherlands Risk/Reward Ratings ...... 44
Rewards ................. 44
Risks . 44
Market Overview ...... 46
Industry Trends And Developments ................. 47
Epidemiology .......... 47
Healthcare Sector .... 48
Healthcare Funding .. 50
Health Insurance ..... 51
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 . . . 52
Healthcare Insurance Developments . 56
Table: Biosimilars Approved In The EU . . . . . . . 57
Research And Development ............. 57
Clinical Trials ......... 60
Biotechnology ......... 63
Regulatory Development .............. 64
Regulatory Developments ............... 65
Intellectual Property Regime ........... 67
Pricing Regime ........ 68
Reimbursement Regime .................. 70
Competitive Landscape ................ 73
Pharmaceutical Industry ................ 73
Table: Pharmaceutical Production, 1995-2010 (EUR '000s) 73
Recent Company Activity ................ 75
Pharmaceutical Wholesale Sector .... 77
Pharmaceutical Retail Sector .......... 78
Company Profile ....... 81
DSM .. 81
Qiagen .................... 85
Pharming Group ....... 88
Merck and Co .............. 92
Pfizer . 95
GlaxoSmithKline ....... 98
Sanofi .................... 100
Novartis ................. 102
Demographic Forecast ............... 105
Demographic Outlook ................... 105
Table: The Netherlands' Population By Age Group, 1990-2020 ('000) . . . . 106
Table: The Netherlands' Population By Age Group, 1990-2020 (% of total) . . . . . . . . . . . . 107
Table: The Netherlands' Key Population Ratios, 1990-2020 108
Table: The Netherlands' Rural And Urban Population, 1990-2020 . . . . . . . . 108
Glossary .................. 109
Methodology ........... 111
Pharmaceutical Expenditure Forecast Model ........ 111
Healthcare Expenditure Forecast Model ............... 111
Notes On Methodology ................. 112
Risk/Reward Ratings Methodology . 113
Ratings Overview ... 114
Table: Pharmaceutical Risk/Reward Ratings Indicators . . . . 114
Indicator Weightings ................... 115

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered ...

Opportunity in the Indian Pharmaceutical Packaging Market - 2015 ; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

Opportunity in the Indian Pharmaceutical Packaging Market - 2015 ; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

  • $ 6 000
  • Industry report
  • January 2015
  • by Feedback Business Consulting

This report provides an insight into the Opportunity in the Indian Pharmaceutical Packaging current market scenario, structure and practices. In depth market scenario includes; - All India pharmaceutical ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.